Revvity, Inc. (NYSE: RVTY) has unveiled Signals Xynthetica™, a new AI-Augmented Design Platform introduced as part of its Signals platform, offering a Models-as-a-Service (MaaS) solution designed to accelerate molecular and materials discovery. This innovative platform integrates in-silico AI-driven design with real-world experimental data, creating a continuous feedback loop that enhances predictive accuracy and drives faster scientific innovation. In the rapidly evolving fields of life sciences and materials research, artificial intelligence and machine learning are transforming discovery from traditional trial-and-error methods to data-driven, predictive design. However, the real-world impact of AI models has often been limited by their isolation from experimental workflows and high-quality lab data. Signals Xynthetica addresses this challenge by embedding AI models directly into the scientific environment, linking AI-generated hypotheses with actual wet-lab results to enable continuous learning and refinement. The platform supports a broad range of in-silico design capabilities, including de novo molecule generation, property prediction, and multi-objective optimization. As a cloud-based MaaS offering, it allows organizations to access, govern, and apply advanced predictive models without the need to build or maintain complex AI infrastructure. This ensures consistent use across projects, with models that can be updated in real time as new experimental data becomes available, and evaluated transparently alongside lab outcomes. “AI has enormous potential to transform how molecules and materials are designed, but that potential is only realized when models are connected to real scientific workflows and data,” said Kevin Willoe, President of Revvity Signals Software. “Signals Xynthetica is about operationalizing predictive science—bringing in-silico design and experimental validation together in a continuous loop to accelerate discovery across industries.” Signals Xynthetica is positioned as a core component of Revvity’s long-term strategy to deliver AI-augmented discovery at scale. The platform emphasizes strong governance, data stewardship, and scientific rigor, ensuring that AI-driven insights are reliable, reproducible, and aligned with research objectives. Pre-registration for the platform is now open, with early access programs expected to launch in the first half of 2026. This marks a significant step forward in Revvity’s mission to empower scientists with intelligent tools that bridge the gap between digital innovation and physical experimentation. Revvity, a leader in health science solutions, serves pharmaceutical and biotech companies, diagnostic labs, academic institutions, and government agencies across more than 160 countries. With over $2.7 billion in revenue in 2024 and approximately 11,000 employees, the company is a member of the S&P 500 and continues to drive innovation from discovery to diagnosis and beyond.